fwiw:
White Mountain Capital Initiates Coverage and Rates Rigel a BUY
PR Newswire, Thursday, September 05, 2002 at 08:30
NANUET, N.Y., Sep 5, 2002 /PRNewswire via COMTEX/ -- White Mountain Capital today released its latest report,"Rigel Pharmaceuticals: Right on Target,"by Director of Biotechnology Research Dr. Oren Levy, Ph.D. and Biotechnology Consultant Sidney VanNess.
The company initiates coverage with a BUY rating."Rigel (Nasdaq: RIGL) combines its proprietary technology with standard discovery techniques to uncover novel, high-quality targets for drug development,"said Dr. Levy."Furthermore, Rigel's initial drug candidates all address large markets,"he said.
Levy also counts Rigel's experienced management and collaborations with large pharmaceutical companies among the strengths of the firm. However, Levy notes that Rigel will likely require additional financing within the year, and that its drug pipeline is just beginning to mature."We believe that Rigel is built upon valuable technology and has promising candidates about to enter the clinic,"he said."Therefore, we initiate coverage with a BUY rating."Copies of the report may be obtained by calling White Mountain Capital at 866-833-5300, visiting whitemountaincapital.com or e-mailing invest@whitemountaincapital.com.
Dr. Oren Levy holds his Ph.D. in neuroscience and is Director of Biotechnology Research for White Mountain Capital, LLC, an independent broker-dealer serving individual, corporate and institutional investors. Member, NASD, SIPC, MSRB. CRD# 104123. |
